FOXO4-DRI

A D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this survival mechanism, FOXO4-DRI selectively triggers apoptosis in senescent cells while leaving healthy cells unaffected — a targeted senolytic approach to reversing age-related cellular deterioration.

• Disrupts the FOXO4-p53 interaction that keeps senescent cells alive
• Liberates p53 to trigger mitochondrial apoptosis in senescent cells
• Selectively targets cells with high FOXO4 nuclear localization (senescent phenotype)

• Active cancer or pre-cancerous conditions
• Immunocompromised individuals
• Pregnancy or breastfeeding
• No human safety profile established

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 7 days. Highly sensitive to degradation.

Published in Cell (2017) by de Keizer et al., FOXO4-DRI demonstrated selective clearance of senescent cells in naturally aged mice, resulting in restored fitness, fur density, and renal function. The D-retro-inverso design confers protease resistance and improved bioavailability. While one of the most scientifically compelling senolytic approaches, it remains strictly in preclinical research with no human trials completed. Its large size and synthesis complexity make it one of the most expensive research peptides.